191 related articles for article (PubMed ID: 37061269)
1. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
;
Lancet; 2023 Apr; 401(10384):1277-1292. PubMed ID: 37061269
[TBL] [Abstract][Full Text] [Related]
2. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
; Peto R; Davies C; Godwin J; Gray R; Pan HC; Clarke M; Cutter D; Darby S; McGale P; Taylor C; Wang YC; Bergh J; Di Leo A; Albain K; Swain S; Piccart M; Pritchard K
Lancet; 2012 Feb; 379(9814):432-44. PubMed ID: 22152853
[TBL] [Abstract][Full Text] [Related]
3. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2019 Apr; 393(10179):1440-1452. PubMed ID: 30739743
[TBL] [Abstract][Full Text] [Related]
4. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
[TBL] [Abstract][Full Text] [Related]
5. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
[TBL] [Abstract][Full Text] [Related]
6. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
8. WITHDRAWN: Multi-agent chemotherapy for early breast cancer.
Clarke MJ
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000487. PubMed ID: 18843612
[TBL] [Abstract][Full Text] [Related]
9. Multi-agent chemotherapy for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2002; (1):CD000487. PubMed ID: 11869577
[TBL] [Abstract][Full Text] [Related]
10. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
[TBL] [Abstract][Full Text] [Related]
11. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
12. Taxanes for adjuvant treatment of early breast cancer.
Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. A systematic overview of chemotherapy effects in breast cancer.
Bergh J; Jönsson PE; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
[TBL] [Abstract][Full Text] [Related]
16. Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials.
Zheng R; Han S; Duan C; Chen K; You Z; Jia J; Lin S; Liang L; Liu A; Long H; Wang S
Medicine (Baltimore); 2015 May; 94(17):e803. PubMed ID: 25929935
[TBL] [Abstract][Full Text] [Related]
17. Taxanes for adjuvant treatment of early breast cancer.
Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Bear HD; Tang G; Rastogi P; Geyer CE; Liu Q; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2015 Sep; 16(9):1037-1048. PubMed ID: 26272770
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Caparica R; Bruzzone M; Poggio F; Ceppi M; de Azambuja E; Lambertini M
Breast Cancer Res Treat; 2019 Feb; 174(1):27-37. PubMed ID: 30465156
[TBL] [Abstract][Full Text] [Related]
20. Platinum-based chemotherapy for early triple-negative breast cancer.
Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]